Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
5,053 total articles
Eugene Nonko, a director at MediaAlpha, Inc., sold 36,600 Class A shares valued at approximately $404,489 over three days in January 2026 through a Rule 10b5-1 trading plan designed to cover RSU tax obligations. MediaAlpha, with a market capitalization of $728 million and current share price of $11.17, is seen as undervalued despite a recent declin…
On January 21, 2026, Mac Armstrong, CEO and Chairman of Palomar Holdings, completed the sale of 5,000 shares totaling approximately $645,000. Despite the sale, Armstrong maintains significant ownership stakes both personally and through a family trust. Palomar recently delivered strong third-quarter 2025 financial results, surpassing earnings expec…
Sam D. Brown, Senior Executive Vice President and Chief Banking Officer at Amalgamated Financial Corporation, conducted a series of stock transactions in January 2026, involving both the sale and acquisition of company shares. These maneuvers took place alongside the publication of Amalgamated Financial's Q4 2025 earnings report, which highlighted …
Phibro Animal Health Corporation directors, including Jack Bendheim and BFI Co., LLC, a significant shareholder, recently sold shares totaling $1.16 million. This move follows a notable 93% share price rise over the past year. The sales occurred as the company prepares for its upcoming earnings announcement and a scheduled executive leadership chan…
Ernie J. Garateix, CEO of Heritage Insurance Holdings, divested over $216,000 worth of company shares on January 20, 2026, executing two sales under an established Rule 10b5-1 trading plan. The company recently reported robust third-quarter earnings surpassing expectations, sustaining its strong financial metrics and impressive stock performance ov…
Rajeev K. Goel, Chief Executive Officer of PubMatic, divested 44,000 shares of the company’s Class A Common Stock on January 20, 2026, generating roughly $332,059. Concurrently, Goel exercised options to acquire an equal number of Class B shares, which were converted into Class A shares. PubMatic's latest quarterly earnings surpassed analyst projec…
Ashley F. Johnson, President and CFO of Planet Labs PBC, recently sold over 150,000 shares of Class A Common Stock, generating over $4 million in proceeds. Concurrently, Planet Labs announced a large-scale contract with the Swedish Armed Forces, accompanied by updated price targets from leading analysts, underscoring the company's growth trajectory…
Seth D. Krauss, Chief Administrative Officer and Senior Counsel at TKO Group Holdings, executed a significant sale of company shares totaling $2.82 million. These transactions, part of a prearranged trading plan, coincide with recent positive analyst revisions and financial developments within the company and related sectors.
Nick Khan, director of TKO Group Holdings, finalized a sale of 7,744 Class A shares worth approximately $1.56 million, while also exercising options and converting restricted stock units recently. TKO trades at a market capitalization of $39 billion, showing strong gross profit margins and an attractive valuation. Analyst sentiment remains positive…
Tara D Mackey, Chief Legal Officer at AZZ Inc., sold nearly 2,800 shares valued at approximately $353,000 under a prearranged trading plan. Concurrently, AZZ reported better-than-expected third-quarter financial results for fiscal 2026, highlighting stronger earnings and revenue growth than market forecasts.
Shane Kapral, Deputy CFO of TKO Group Holdings, executed a sale of 1,851 shares of Class A Common Stock worth nearly $375,000 over a two-day period, accompanied by a simultaneous exercise of stock options. Recent corporate developments include an upward revision of TKO’s stock price target, expansion of its credit facility, and strategic partnershi…
Janet Dillione, a director at CorMedix Inc, sold 10,000 shares in late January 2026, executing transactions between $6.85 and $6.90 per share, totaling $68,800. Post-sale, Dillione retains direct ownership of 38,473 shares. The company disclosed preliminary Q4 2025 net revenue of approximately $127 million, with 2025 fullyear revenue at $310 millio…
Jeffrey Richart Geygan, serving as interim CEO at Rocky Mountain Chocolate Factory, Inc., acquired an additional 11,300 shares, enhancing his overall stake in the company. This insider purchase coincides with recent quarterly financial disclosures that show revenue growth tempered by profitability issues and a modest decline in sales. With the stoc…
Global Value Investment Corp, owning a 10% stake in Rocky Mountain Chocolate Factory, acquired an additional 11,300 shares at $1.9781 each, totaling over $22,000. This move comes even as Rocky Mountain Chocolate Factory reports ongoing financial challenges, including weak profitability metrics and a modest market capitalization. Recent quarterly ea…
Pliant Therapeutics' CFO, Keith Lamont Cummings, sold over 24,000 shares in January 2026, a move occurring alongside a significant decline in the company's share price over the past year. Despite financial setbacks, the company reported promising clinical trial results and notable executive changes.
Lily Cheung, Chief Human Resource Officer at Pliant Therapeutics (NASDAQ:PLRX), sold 7,534 shares worth approximately $9,643 in late January. Concurrently, the company shared positive interim Phase 1 data for its investigational cancer therapy and disclosed recent executive movements, highlighting ongoing changes at the firm.
Bernard Coulie, President and CEO of Pliant Therapeutics, recently sold shares to cover tax liabilities tied to employee stock vesting, coinciding with notable clinical trial advances and executive shifts within the company. These developments highlight ongoing operational and strategic adjustments affecting stakeholders across the pharmaceutical s…
Natera Inc's Chief Financial Officer, Michael Burkes Brophy, sold over 60,000 shares recently worth approximately $14.6 million. Concurrently, the company revealed encouraging fourth-quarter 2025 financial results, significant test volume increases, and advancements in cancer diagnostics through collaborative trials and new AI models enhancing recu…
Minnie Kuo, Chief Operating Officer of Pliant Therapeutics, recently sold 6,917 shares of the company’s stock to satisfy tax obligations related to vested restricted stock units. This sale, executed throughout January 20-22, 2026, totaled $8,853 and reflects a weighted price range between $1.245 and $1.33 per share. Pliant’s stock has experienced a…
Natera’s CEO Steven Leonard Chapman sold over seventy-three thousand shares worth approximately $17.2 million to cover tax liabilities from vested restricted stock units. Amid this, the company reported strong fourth-quarter 2025 financials exceeding analyst estimates and advanced its oncology and genetic testing pipeline through collaborations and…
Owlet, Inc.'s President and CEO Jonathan Harris sold 2,311 shares of the company's common stock on January 20, 2026, generating proceeds exceeding $30,000. Concurrently, Owlet is pushing forward with multiple initiatives including insurance partnerships and international product launches to enhance its pediatric health monitoring profile.
Casey O’Connor, Stitch Fix’s Chief Legal Officer, sold over $725,000 worth of company stock through a scheduled trading plan in January 2026. Concurrently, the company reported revenue exceeding forecasts and extended its credit agreement maturity, signaling positive financial movements despite client declines.
Owlet, Inc.'s Chief Financial Officer Amanda Crawford recently divested a modest portion of her shares, totaling $2,439, primarily to address tax and fee commitments linked to restricted stock units. This transaction comes as Owlet's stock maintains robust gains over the past year. Meanwhile, the company is actively broadening its market footprint …
Daniel Rabinowitz, Natera's SEC and Chief Legal Officer, sold nearly $4.6 million worth of company stock over two days in January 2026 while also acquiring shares through restricted stock unit exercises. This insider activity follows Natera's impressive preliminary fourth-quarter financial results and announcements of innovative developments in can…
Solomon Moshkevich, President of Clinical Diagnostics at Natera, recently sold over 23,400 shares of the company's common stock between January 20 and 21, 2026, generating proceeds of approximately $5.5 million. The sales were made under a pre-arranged trading plan to cover tax liabilities from vested Restricted Stock Units. Natera’s shares have ga…
